Dual Hormone Closed Loop in Type 1 Diabetes

Diabetes Clinical Trial

— DARE  

Official title:

Dual Hormone Closed Loop in Type 1 Diabetes: a Randomized Trial (DARE)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05669547
• Other study ID #: 22/671
• Status: Recruiting
• Phase: N/A
• Start date: October 3, 2023
• Est. completion date: January 1, 2026

Study information

• Verified date: June 2024
• Source: UMC Utrecht
• Contact: Milena Jancev, MD
• Phone: +31 88 75 5555
• Email: m.jancev-3[@]umcutrecht.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a 12 month open-label, two-arm randomised parallel-group trial in adult type 1 diabetes patients executed in 14 centres in the Netherlands. The aim of this study is to determine the long-term clinical effectiveness of treatment with a dual-hormone (insulin and glucagon) fully closed loop system during 12 months compared to the current most used care and to the currently most advanced technological care. Secondary objectives include the assessment of cost-effectiveness, Patient Reported Outcome Measures (PROMs), other glycaemic outcomes and safety.

Description:

Rationale: Patients with type 1 diabetes mellitus (T1DM) require lifelong insulin therapy. Insulin therapy improves but does not fully normalise blood glucose levels with current therapies. Current therapies include subcutaneous insulin injection or subcutaneous insulin infusion, combined with a device to measure glucose levels (finger stick, intermittent sensor or continuous glucose monitoring). Although having provided a huge improvement in glycaemic control, patients have to work hard every day and still have to calculate mealtime boluses. An automated insulin delivery device covering both basal and prandial insulin requirement would mean another great leap forwards. The dual-hormone fully closed loop (DHFCL) provides such a new strategy of automated insulin delivery coupled with targeted glucagon infusion as insulin-antagonist to even more approximate normal physiology.

Objective: To determine the long-term clinical effectiveness of treatment with a dual-hormone (insulin and glucagon) fully closed loop system during 12 months compared to the current most used care and to the currently most advanced technological care. Secondary objectives include the assessment of cost-effectiveness, Patient Reported Outcome Measures (PROMs), other glycaemic outcomes and safety.

Study design: A 12 month open-label, two-arm randomised parallel-group trial. Study population: Adult (age ≥18 years) patients with T1DM for at least 1 year with an HbA1c at entry ≤ 91 mmol/mol.

Intervention: The study includes two separately randomised arms, defined by current diabetes treatment. In one arm, patients currently on Multiple Daily Injections (MDI; at least once daily long-acting insulin and thrice daily short-acting insulin) in combination with continuous or flash glucose monitoring (CGM or FGM; currently the most used strategy) are 1:1 randomised to either the intervention, i.e. the DHFCL, or continuation of their current treatment. In the other arm, patients currently on hybrid closed loop treatment (HCL; presently the most advanced diabetes control treatment) are 1:1 randomised to either the intervention or continuation of their current care.

Main study parameters/endpoints: The main study endpoint is the Time in Range (TIR; % of time spent in the 3.9-10 mmol/l target range) at 12 months, which will be compared between the intervention and the control treatment within each arm. Secondary endpoints include cost-effectiveness, PROMs, other glycaemic outcomes, safety measures and device-related outcomes.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 240
• Est. completion date: January 1, 2026
• Est. primary completion date: October 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age between 18 and 75 years;

• Diagnosed with type 1 diabetes mellitus at least one year ago;

• HbA1c = 91 mmol/mol;

• Treated with either MDI with FGM/CGM or treated with HCL:

• MDI+FGM/CGM for = 3 months with an adequate sensor use during at least 70% of the time in the month prior to screening (based on sensor usage from the download summary report of the FGM/CGM);

• HCL for = 3 months with a frequency of use = 70% of the time in auto mode over the previous month prior to screening;

• Does not reach the treatment goals over the last 8 weeks:

• for MDI+FGM/CGM: subject has a TIR <80% or Time Below Range (TBR) >4%;

• for HCL: subject has a TIR <80% or TBR >4%;

• Willing to take or switch to insulin Humalog when randomized to the intervention DHFCL arm;

• Under treatment in one of the participating centres;

• Willing and able to sign informed consent;

• Access to internet at home (for DHFCL data upload).

Exclusion Criteria:

• Current use of non-approved HCL device;

• BMI >35 kg/m2;

• eGFR<30 mL/min/1.73m2;

• Plan to change usual diabetes regimen in the next 3 months;

• Current participation in another diabetes-related clinical trial;

• Actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or device in the last 2 weeks before enrolment into this study, as per investigator judgment;

• Established history of allergy or severe reaction to adhesive or tape that must be used in the study;

• Use of oral glucose-lowering medication;

• Active retinopathy or painful neuropathy;

• Daily use of acetaminophen during the trial (all arms), as this may influence the sensor glucose measurements. Incidental use with a maximum of e.g. 3 daily doses of 1000mg paracetamol for a maximum of 3 consecutive days is allowed

• Limited ability to see, and to hear or feel alarm signals of the closed loop system;

• Current pregnancy, breast feeding or planning to become pregnant in the 12 months of the trial or using ineffective birth control methods;

• Presence of a medical or psychiatric condition, longstanding serious adherence problems, anticipated problems in handing over diabetes control to a device or use of a medication that, in the judgment of the investigator, clinical protocol chair, or medical monitor, could compromise the results of the study or the safety of the participant.

Related Conditions & MeSH terms

• Diabetes
• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Diabetes type1

Intervention

Device:
• dual hormone fully closed loop (DHFCL)
dual hormone fully closed loop consisting of an algorithm, sensors and both insulin and glucagon infusion.

Locations

Country	Name	City	State
Netherlands	Meander MC	Amersfoort
Netherlands	Amsterdam UMC, AMC	Amsterdam
Netherlands	Amsterdam UMC, VUmc	Amsterdam
Netherlands	OLVG	Amsterdam
Netherlands	Gelre Ziekenhuis	Apeldoorn
Netherlands	Rijnstate	Arnhem
Netherlands	Catharina Ziekenhuis	Eindhoven
Netherlands	Martini Ziekenhuis	Groningen
Netherlands	UMC Groningen	Groningen
Netherlands	Tergooi Ziekenhuis	Hilversum
Netherlands	LUMC	Leiden
Netherlands	St. Antonius	Nieuwegein
Netherlands	UMC Utrecht	Utrecht
Netherlands	Isala Klinieken	Zwolle

Sponsors (3)

Lead Sponsor	Collaborator
UMC Utrecht	Dutch National Health Care Institute, Inreda Diabetic B.V.

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Patient reported daily insulin use control group	The amount of daily insulin use reported by the patients in the control group	at 3, 6, 9 and 12 months
Other	Weight (kg) at baseline and 12 months	Change of weight 0-12 months	12 months
Other	Blood pressure (SBP/DBP in mmHg) at baseline and 12 months	Change of blood pressure and heart rate 0-12 months	12 months
Other	Heart rate (/min) at baseline and 12 months	Change of heart rate 0-12 months	12 months
Other	Frequency of unplanned patient contact with the diabetes team	Evaluating whether the DHFCL imposes more unplanned patient contact moments	at 3, 6, 9 and 12 months
Other	Concomitant medication, at screening, baseline, 3, 6, 9 and 12 months	Evaluation of medication	at screening, baseline, 3, 6, 9 and 12 months
Other	Continuation rate of the DHFCL	Expressed as the percentage of participants that continue DHFCL treatment after 1 year of use	at 12 months
Other	Reasons for discontinuation of the DHFCL treatment.	Patients will be asked by the physician what the reason of discontinuation is when discontinuing the DHFCL treatment before the end of study	at 3, 6, 9 and 12 months
Primary	Time in Range (TIR) at 12 months (measured with an independent FSL Pro IQ sensor)	TIR (% of time spent in the 3.9-10 mmol/l target range) at 12 months, which will be compared between the intervention and the control treatment within each arm.	12 months
Secondary	World Health Organization-Five Well-Being Index (WHO-5) score (Patient reported outcomes (PROMs)	The World Health Organisation- Five Well-Being Index (WHO-5) is a short self-reported measure of current mental wellbeing.	at 0, 3, 6, 9 and 12 months
Secondary	Health-related quality of life scores (EQ-5D-5L) (Patient reported outcomes (PROMs)	As described on the Euroqol website, the EQ-5D-5L measures mobility, self-care, usual activities, pain/discomfort and anxiety/depression.	at 0, 3, 6, 9 and 12 months
Secondary	Problem Areas In Diabetes (PAID-5) score (Patient reported outcomes (PROMs)	Evaluates problem areas in diabetes	at 0, 3, 6, 9 and 12 months
Secondary	Diabetes Treatment and Satisfaction Questionnaire status and change (DTSQ-s and DTSQ-c) scores (Patient reported outcomes (PROMs)	Measurement of treatment satisfaction	at 0, 3, 6, 9 and 12 months
Secondary	Hypoglycaemia Fear Survey-II (HFS-II) Worry subscale score; (Patient reported outcomes (PROMs)	Measures hypoglycaemia fear	at 0, 3, 6, 9 and 12 months
Secondary	Pittsburgh Sleep Quality Index score (Patient reported outcomes (PROMs)	Measures sleep quality and duration	at 0, 3, 6, 9 and 12 months
Secondary	Insulin delivery systems: perceptions, ideas, reflections and expectations (INSPIRE) scores (Patient reported outcomes (PROMs)	Measures ideas, perceptions and expectations of the insulin device - only for HCL (control) and DHFCL groups	at 0, 3, 6, 9 and 12 months
Secondary	Hypoglycaemia unawareness (Gold-Clarke) (Patient reported outcomes (PROMs)	Measurement of hypoglycaemia unawareness	at 0 and 12 months
Secondary	Cost-effectiveness: cost per quality adjusted life year.	To determine the cost-effectiveness of treatment with the DHFCL. Including data: Medical Consumption Questionnaire (MCQ), at 0, 3, 6, 9 and 12 months; Productivity Cost Questionnaire (PCQ), at 0, 3, 6, 9 and 12 months; Detailed hospital health care consumption for each individual patient (collected from electronic patient files, including unplanned contact moments) Cost effectiveness: cost per quality adjusted life year.	12 months
Secondary	Other glycaemic outcomes	Including Time Below Range (TBR), Time Above Range (TAR), glycaemic variability, number of hypoglycemic events and HbA1c.	at 0, 3, 6, 9 and 12 months
Secondary	Time Above Range (TAR) Other glycaemic outcomes	Measured with an independent Freestyle Libre Pro IQ sensor; level 1 and 2 hyperglycaemia: >10.0 mmol/l; level 2 hyperglycaemia: >13.9 mmol/l;	at 0, 3, 6, 9 and 12 months
Secondary	Time Below Range (TBR) Other glycaemic outcomes	Measured with an independent Freestyle Libre Pro IQ sensor; level 1 and 2 hypoglycaemia: <3.9 mmol/l; level 2 hypoglycaemia: <3.0 mmol/l;	at 0, 3, 6, 9 and 12 months
Secondary	Number of hypoglycaemic events Other glycaemic outcomes	Measured with an independent Freestyle Libre Pro IQ sensor defined as glucose <3.0 mmol/l for 15 consecutive minutes when the time between two successive events is less than 30 minutes, they will be combined and counted as one event	at 0, 3, 6, 9 and 12 months
Secondary	Mean glucose Other glycaemic outcomes	Measured with an independent Freestyle Libre Pro IQ sensor; day and night; day: from 06:00 to 23:59 hours; night: from 00:00 to 05:59 hours;	at 0, 3, 6, 9 and 12 months
Secondary	Glycaemic variability Other glycaemic outcomes	Based on independent Freestyle Libre Pro IQ sensor data; Coefficient of variation; Standard deviation.	at 0, 3, 6, 9 and 12 months
Secondary	HbA1c Other glycaemic outcomes	venipuncture; Mean; Percentage patients achieving HbA1c = 53 mmol/mol.	at 0, 3, 6, 9 and 12 months
Secondary	Long-term safety outcomes	To assess long-term safety of the DHFCL, including the incidence of (severe) adverse events, incidence of device issues and the effects of excluding daily use of acetaminophen on non steroidal inflammatory drug (NSAIDs) use and associated drug complications rate.	12 months
Secondary	Daily insulin use (units/day) DHFCL outcomes	Measured by DHFCL device	at 3, 6, 9 and 12 months
Secondary	daily glucagon use.DHFCL outcomes	Measured by DHFCL device Daily insulin use, daily glucagon use and percentage of time glucose control algorithm active at 0, 3, 6, 9 and 12 months.	at 3, 6, 9 and 12 months
Secondary	Percentage of time glucose control algorithm active DHFCL outcomes	Measured by DHFCL device	at 3, 6, 9 and 12 months

External Links

•   DARE trial website (Dutch)